Intelligent Bio Solutions completes interference study for fingerprint codeine screening system ahead of FDA filing
INBS•Study findings and next steps
The study indicates common external contaminants on fingertips did not compromise system performance in field-like conditions.
The work feeds a broader evidence package, and the 510(k) submission remains targeted for calendar H2 2026.
Clinical interference study supports FDA filing
Intelligent Bio Solutions completed a clinical interference study supporting its FDA 510(k) filing for U.S. clearance to detect codeine.
Results have not been presented; data analysis is underway with independent verification planned using LC-MS/MS.
